GE Board of Directors Authorizes Regular Quarterly Dividend
Get Alerts GE Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.5%
Revenue Growth %: +16.4%
Join SI Premium – FREE
BOSTON--(BUSINESS WIRE)-- The Board of Directors of GE (NYSE: GE) today declared a $0.08 per share dividend on the outstanding common stock of the Company. The dividend is payable October 25, 2021 to shareholders of record at the close of business on September 27, 2021. The ex-dividend date is September 24, 2021.
About GE
GE (NYSE: GE) rises to the challenge of building a world that works. For more than 125 years, GE has invented the future of industry, and today the company’s dedicated team, leading technology, and global reach and capabilities help the world work more efficiently, reliably, and safely. GE’s people are diverse and dedicated, operating with the highest level of integrity and focus to fulfill GE’s mission and deliver for its customers. www.ge.com
GE’s Investor Relations website at www.ge.com/investor and our corporate blog at www.ge.com/reports and @GE_Reports on Twitter, as well as GE’s Facebook page and Twitter accounts, contain a significant amount of information about GE, including financial and other information for investors. GE encourages investors to visit these websites from time to time, as information is updated and new information is posted.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210910005468/en/
GE Investors:
Steve Winoker, 617.443.3400
[email protected]
GE Media:
Mary Kate Mullaney, 202.304.6514
[email protected]
Source: GE
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bomb Pop Will Distribute 100,000 Free Samples at Droplight Grand Park Sports Campus to Cool Down Youth Sports Players during July 17–26 Westfield, Indiana, Event
- Capstone Converts $700,000 of Surplus Inventory to Sales Without Discounting Following CSI Acquisition
- Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Twitter, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share